Clinical Trial Detail

NCT ID NCT02609776
Title Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

lung non-small cell carcinoma

Therapies

JNJ-61186372

Carboplatin + JNJ-61186372 + Pemetrexed Disodium

JNJ-61186372 + Lazertinib

Age Groups: adult senior

No variant requirements are available.